The Filing Desk

Cronos Group

CRON · Nasdaq · Consumer Staples · Financials, fiscal 2016 to 2025

CRON · Last close · November 19, 2026
$3.08
Value Cronos Group yourself

Cronos Group's revenue rose 24.6% to $147 million in fiscal 2025. Its operating margin was −11.9%, up from −65.1% a year earlier. Free cash flow was $0 million, down 97.7%. It paid out $10 million in dividends and buybacks, 6538% of free cash flow. The diluted share count fell 0.5%.

CRONOS GROUP INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001656472-26-000016 Updated
Revenue
$147M
24.6%
Operating margin
−11.9%
53.2 pts
Net income
−$9M
$41M a year earlier
Free cash flow
$0M
97.7%
Return on equity
−0.9%
4.7 pts
Market cap
$1.1B
Nov 19 close
P/E
18.1x
On $0.17 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Cronos Group does

Cronos Group is a cannabis company based in Ontario, Canada. It grows, processes and sells cannabis products, including dried flower, extracts, topicals and edibles, under brands such as Spinach, PEACE NATURALS, LIT and Lord Jones. It sells in Canada and in Israel, where it operates under the certifications needed for medical cannabis.

Cronos reports one segment. In Canada it runs a licensed producer, Peace Naturals, with production facilities in Stayner, Ontario, and it owns half of Cronos GrowCo, whose licensed facilities are its main source of cannabis. It says its strategy is to build a brand portfolio, a global sales and distribution network and an efficient supply chain, and to create and earn money from its own intellectual property.

It has agreed to buy CanAdelaar, a deal that still needs to close.

Its biggest risks, as it describes them

  • Having a short operating history and possibly not reaching or keeping profitability.
  • Wholesale cannabis price swings that could hurt its results.
  • Its joint ventures and its reliance on importing cannabis into Israel.
  • The planned CanAdelaar deal may be delayed, cost more or fail to close.
  • Acquisitions that may need goodwill and intangible assets to be written down.
From Cronos Group's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both. Where the filings' structured data doesn't give a year's net income, the column is blank.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2019 to 2024, earnings per share fell 49.4% a year and net income 48.8% a year, as new shares raised the share count by 12% and diluted each share's earnings. Cronos Group then lost money in fiscal 2025.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red. Where the filings' structured data doesn't give a year's earnings per share, the column is blank.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1,005878862859832
Debt incl. finance leases—————
Net debt (negative means net cash)—————
Net debt to EBITDA—————
Debt to equity—————
Interest coverage−10,813.7x−8,571.4x———
Current ratio19.9x14.1x22.5x18.8x19.6x
Quick ratio19.2x13.5x21.8x18.2x18.6x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Cronos Group's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Cronos Group reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score———
Rule of 40−51.4%40.3%24.7%
Altman Z''31.9026.9128.18
Accruals ratio−2.6%1.9%−3.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailPassFail
Cash from operations is positiveFailPassPass
Return on assets rosePassPassFail
Cash from operations exceeds net incomePassFailPass
Debt fell relative to assets———
Current ratio rosePassFailPass
Share count didn't riseFailFailPass
Gross margin roseFailPassPass
Revenue rose relative to assetsPassPassPass
F-score———
Companies that report no gross profit are scored on the other eight.

Compare

Put Cronos Group side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Cronos GroupFY2524.6%−11.9%0.1%———
Niagen BioscienceFY2529.9%12.6%——−3.8x6Compare
LifeVantageFY26−20.1%3.3%3.6%30.8%−1.7x5Compare
MannatechFY25−8.3%−0.4%−4.0%—−4.1x2Compare
FitLife BrandsFY2526.4%12.3%9.1%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—3122447658787118147
Revenue growth——285.2%95.9%96.7%38.2%34.4%0.6%34.8%24.6%
Gross profit—26−18−26−1815122563
Research and development—0212202213644
Operating income—−6−20−153−219−292−111−85−76−17
Net income—−2−221,166−73−396−169−7441−9
Diluted EPS (US$)—−0.01−0.123.33−0.21−1.07−0.45−0.190.11−0.02
Diluted shares (millions)78177172343352370377381386384
Cash flow
Cash from operations—−4−8−131−145−154−89−431926
Capital expenditure—3388393111421226
Free cash flow—−37−96−170−176−165−92−4560
Dividends paid0000000000
Share buybacks00000000010
Acquisitions000224000000
Stock-based compensation—2812151015997
Balance sheet at fiscal year end
Cash and short-term investments37241,5061,2901,005878862859832
Debt incl. finance leases——————————
Total assets——1842,0901,9261,3981,2131,1401,1661,197
Total liabilities——353412186472445554
Shareholders' equity22641481,7501,7111,3371,1441,1001,0641,094
Margins and ratios
Gross margin—50.0%51.3%−74.1%−55.3%−27.2%17.8%13.7%21.4%42.8%
Operating margin—−194.5%−168.7%−645.5%−469.6%−452.2%−128.4%−97.2%−65.1%−11.9%
Net margin—−47.1%−178.5%4,911.6%−156.6%−613.5%−194.5%−84.8%34.9%−6.4%
Free cash flow margin—−1,182.2%−790.6%−715.2%−377.3%−255.2%−106.5%−52.0%5.5%0.1%
Rule of 40 (growth + FCF margin)——−505.4%−619.2%−280.6%−217.0%−72.2%−51.4%40.3%24.7%
Return on capital——————————
Return on equity———122.9%−4.2%−26.0%−13.6%−6.6%3.8%−0.9%
Return on assets———102.6%−3.6%−23.8%−12.9%−6.3%3.6%−0.8%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Cronos Group's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Cronos Group.